Chris is currently Senior Vice President, Head Business Development for GSK based in the UK. Chris and his team are responsible for all of GSK's business development activities globally covering the scouting, transacting and alliance management of all new investment opportunities. Chris and his team led the recent $2B proposed acquisition of Bellus Health and a licensing deal with WuXi Biologics for multiple novel bi- & multi-specific T cell engagers in oncology.
Prior to this Chris worked in the UK at AstraZeneca (AZ) for over 19 years. Chris held the role of Vice President & Head of Oncology Business Development in Oncology Research & Development. Chris and his team led the evaluation and investment cases for AZ’s major $6.9B and $6B clinical stage co-development/co-promotion deals with Daiichi-Sankyo for novel antibody drug conjugates (ADCs). Chris also led AZ’s $6.4B acquisition of Acerta Pharma for a best-in-class BTK inhibitor in haematology.
Chris holds a Ph.D in Chemistry from the University of Bristol, UK and a first class honours degree in Chemistry from the University of Sheffield, UK.
Prior to this Chris worked in the UK at AstraZeneca (AZ) for over 19 years. Chris held the role of Vice President & Head of Oncology Business Development in Oncology Research & Development. Chris and his team led the evaluation and investment cases for AZ’s major $6.9B and $6B clinical stage co-development/co-promotion deals with Daiichi-Sankyo for novel antibody drug conjugates (ADCs). Chris also led AZ’s $6.4B acquisition of Acerta Pharma for a best-in-class BTK inhibitor in haematology.
Chris holds a Ph.D in Chemistry from the University of Bristol, UK and a first class honours degree in Chemistry from the University of Sheffield, UK.
Speaking In
3:00 PM - 4:00 PM
Wednesday, June 7
